Pills masthead

News Releases

Archives: Search / 2022 / 2021 / 2020 / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013

20122011201020092008200720062004

Jun 1, 2022

Approximately Half of the Planned Number of Subjects Have Received the First Dose, With No Reported Serious Adverse Events Study Progressing On Schedule Topline Results Expected Later This Year...

More
May 12, 2022

-- Current Drug Market Shortage Exists for Fludarabine Phosphate, An Injectable Chemotherapeutic Medication; Marketing Anticipated to Commence Later This Calendar Year -- PHILADELPHIA, May 12,...

More
May 4, 2022

Q3 Business and Financial Highlights: Net Sales were $78.4 Million Cash in Excess of $106 Million at March 31 Completed Sale of Liquid Manufacturing Plant for $10.5 Million; Major Elements of...

More
Apr 27, 2022

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2022 third quarter on Wednesday, May 4, 2022, after the market closes. Lannett management...

More
Mar 29, 2022

--First Patient Dosed, Topline Study Results Expected Later This Year; Potential BLA Filing in Early 2023 and Launch in the First Half of 2024-- TREVOSE, Pa., March 29, 2022 /PRNewswire/ --...

More
Mar 18, 2022

Lannett Company, Inc. (NYSE: LCI) today announced that it has received written notice from the New York Stock Exchange (NYSE) dated March 14, 2022, notifying the company that it is not in...

More
Mar 4, 2022
--Company Announces Receipt of FDA Complete Response Letter (CRL) for Generic Advair DiskusĀ® Product; Based on Preliminary Review, Company Expects At Least a Second Review Cycle--

Lannett Company, Inc. (NYSE: LCI) today announced that the company will participate in a fireside chat at the 34th Annual ROTH Conference on March 14, 2022 at 12:30 p.m. PT at The Ritz Carlton, in...

More
Mar 4, 2022

Lannett Company, Inc. (NYSE: LCI) today announced that it has received written notice from the New York Stock Exchange (NYSE) dated March 2, 2022, notifying the company that it is not in...

More
Mar 4, 2022
--Transaction a Key Element of Company's Plan to Streamline Operations and Reduce Costs; Proceeds Further Strengthens Cash Position--

Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into material definitive agreements to sell its liquid drug manufacturing facility in Carmel, NY, as well as equipment located...

More
Feb 3, 2022
-- Q2 Business and Financial Highlights:

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2022 second quarter ended December 31, 2021. "For the quarter, ongoing and increasing competitive pricing pressure...

More
 
Price Data
NYSELCI